RPHM
Income statement / Annual
Last year (2023), Reneo Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Reneo Pharmaceuticals, Inc.'s net income was -$77.39 M.
See Reneo Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$525,000.00 |
$529,000.00 |
$50,000.00 |
$37,000.00 |
$34,000.00 |
| Gross Profit |
-$525,000.00 |
-$529,000.00 |
-$50,000.00 |
-$37,000.00 |
-$34,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$56.61 M
|
$37.71 M
|
$28.17 M
|
$15.94 M
|
$13.10 M
|
| General & Administrative
Expenses |
$25.79 M
|
$16.14 M
|
$11.65 M
|
$3.61 M
|
$2.38 M
|
| Selling & Marketing
Expenses |
$26.44 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$25.79 M
|
$16.14 M
|
$11.65 M
|
$3.61 M
|
$2.38 M
|
| Other Expenses |
$650,000.00 |
$1.89 M |
$48,000.00 |
$87,000.00 |
$3.04 M |
| Operating Expenses |
$83.05 M |
$53.85 M |
$39.82 M |
$19.55 M |
$15.47 M |
| Cost And Expenses |
$83.05 M |
$53.85 M |
$39.82 M |
$19.55 M |
$15.47 M |
| Interest Income |
$0.00 |
$1,893.00 |
$48.00 |
$87,000.00 |
$456,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$170,000.00
|
$529,000.00
|
$50,000.00
|
$37,000.00
|
$34,000.00
|
| EBITDA |
-$82.23 M
|
-$53.76 M
|
-$39.77 M
|
-$19.52 M
|
-$15.44 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$5.67 M
|
$1.89 M
|
$48,000.00
|
$87,000.00
|
$3.04 M
|
| Income Before Tax |
-$77.39 M |
-$51.96 M |
-$39.77 M |
-$19.47 M |
-$12.44 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$650,000.00 |
-$1.89 M |
-$186,558.00 |
-$169,297.00 |
-$137,860.00 |
| Net Income |
-$77.39 M |
-$50.06 M |
-$39.77 M |
-$19.47 M |
-$12.44 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-25.23 |
-2.04 |
-2.19 |
-0.8 |
-1.6 |
| EPS Diluted |
-25.23 |
-2.04 |
-2.19 |
-0.8 |
-1.6 |
| Weighted Average Shares
Out |
$3.07 M
|
$24.50 M
|
$18.14 M
|
$24.21 M
|
$7.79 M
|
| Weighted Average Shares
Out Diluted |
$3.07 M
|
$24.50 M
|
$18.14 M
|
$24.21 M
|
$7.79 M
|
| Link |
|
|
|
|
|
